Replies to post #99120 on Biotech Values

[DFRAI]

MNTA - motionman

MNTA lovenox success or failure hinges on a crosseye fda employee who for the last 4 years starred at documents and shuffled papers back and forth

The entire company future as far as lovenox, copaxone, fob follow on hinges on this decision - so pretty much is a house of cards at this time.

Management should not have allowed this to happen - M118 should have been partnered already and new funds raised if needed.

Its an explosive situation with 3-4 dollars bottom if negative and 40 top range.